Price Target Changed • May 29
Price target decreased by 17% to US$6.67 Down from US$8.00, the current price target is an average from 3 analysts. New target price is 232% above last closing price of US$2.01. Stock is down 40% over the past year. The company is forecast to post a net loss per share of US$0.93 next year compared to a net loss per share of US$1.05 last year. New Risk • May 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$94.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$43m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$279k sold). Market cap is less than US$100m (US$94.7m market cap). Annonce • May 15
Rapid Micro Biosystems, Inc. Reaffirms Its Earnings Guidance for the Year 2026 Rapid Micro Biosystems, Inc. reaffirmed its earnings guidance for the year 2026. The Company is reaffirming its full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements, at least 25 system validations and gross margin percentage of approximately 20%. Reported Earnings • May 15
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: US$0.31 loss per share (further deteriorated from US$0.26 loss in 1Q 2025). Revenue: US$8.00m (up 11% from 1Q 2025). Net loss: US$14.3m (loss widened 27% from 1Q 2025). Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. New Risk • May 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$37m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$279k sold). Annonce • May 07
Rapid Micro Biosystems, Inc. to Report Q1, 2026 Results on May 13, 2026 Rapid Micro Biosystems, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 13, 2026 Annonce • Apr 09
Rapid Micro Biosystems, Inc., Annual General Meeting, May 21, 2026 Rapid Micro Biosystems, Inc., Annual General Meeting, May 21, 2026. New Risk • Apr 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$37m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Significant insider selling over the past 3 months (US$368k sold). Market cap is less than US$100m (US$98.2m market cap). Annonce • Mar 28
Rapid Micro Biosystems, Inc. Announces Management Changes, Effective April 10, 2026 Rapid Micro Biosystems, Inc. announced that on March 23, 2026, Mr. John Wilson, Chief Operating Officer of Rapid Micro Biosystems, Inc., notified the Company of his intention to depart from the Company, effective April 10, 2026, in order to spend more time with his family. Mr. Wilson's departure is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with Mr. Wilson's anticipated departure, Mr. Robert Spignesi, the Company's President and Chief Executive Officer, in addition to his current positions, will assume the role of the Company's principal operating officer, effective April 10, 2026. The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K related to Mr. Spignesi was previously disclosed in the Company's definitive proxy statement filed on April 8, 2025. New Risk • Mar 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$37m net loss in 2 years). Significant insider selling over the past 3 months (US$327k sold). Reported Earnings • Mar 15
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$1.06 loss per share. Revenue: US$33.6m (up 20% from FY 2024). Net loss: US$47.1m (flat on FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.3%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Annonce • Mar 13
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Year 2026 Rapid Micro Biosystems, Inc. provided revenue guidance for the year 2026. For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million. Recent Insider Transactions • Feb 26
CEO, President & Director recently sold US$149k worth of stock On the 19th of February, Robert Spignesi sold around 38k shares on-market at roughly US$3.89 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$197k. Annonce • Feb 25
Rapid Micro Biosystems, Inc. to Report Q4, 2025 Results on Mar 12, 2026 Rapid Micro Biosystems, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026 Annonce • Jan 14
Rapid Micro Biosystems, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025 Rapid Micro Biosystems, Inc. provided unaudited earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects record revenue of approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.
For the year, the Company expects revenue of approximately $33.6 million, representing growth of approximately 20% compared to the prior year. Reported Earnings • Nov 09
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.26 loss per share. Revenue: US$7.84m (up 3.1% from 3Q 2024). Net loss: US$11.5m (loss widened 1.6% from 3Q 2024). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) missed analyst estimates by 6.1%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Annonce • Nov 08
Rapid Micro Biosystems, Inc. Raises Earnings Guidance for the Full Year 2025 Rapid Micro Biosystems, Inc. raised earnings guidance for the Full year 2025. For the period, the company expects total revenue guidance of at least $33.0 million. Annonce • Oct 29
Rapid Micro Biosystems, Inc. to Report Q3, 2025 Results on Nov 07, 2025 Rapid Micro Biosystems, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 07, 2025 Reported Earnings • Aug 13
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.27 loss per share (improved from US$0.29 loss in 2Q 2024). Revenue: US$7.26m (up 9.7% from 2Q 2024). Net loss: US$11.9m (loss narrowed 5.7% from 2Q 2024). Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 6.6%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Annonce • Aug 01
Rapid Micro Biosystems, Inc. to Report Q2, 2025 Results on Aug 12, 2025 Rapid Micro Biosystems, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 12, 2025 Recent Insider Transactions Derivative • Jul 13
CEO, President & Director exercised options and sold US$117k worth of stock On the 10th of July, Robert Spignesi exercised options to acquire 34k shares at no cost and sold these for an average price of US$3.47 per share. This trade did not impact their existing holding. For the year to December 2020, Robert's total compensation was 49% salary and 51% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Robert's direct individual holding has decreased from 321.64k shares to 14.77k. Company insiders have collectively bought US$66k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • May 10
First quarter 2025 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2024) First quarter 2025 results: US$0.26 loss per share (improved from US$0.31 loss in 1Q 2024). Revenue: US$7.21m (up 28% from 1Q 2024). Net loss: US$11.3m (loss narrowed 16% from 1Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Annonce • Apr 25
Rapid Micro Biosystems, Inc. to Report Q1, 2025 Results on May 09, 2025 Rapid Micro Biosystems, Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025 Annonce • Apr 10
Rapid Micro Biosystems, Inc., Annual General Meeting, May 22, 2025 Rapid Micro Biosystems, Inc., Annual General Meeting, May 22, 2025. New Risk • Mar 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$39m net loss in 2 years). Market cap is less than US$100m (US$98.1m market cap). Reported Earnings • Mar 02
Full year 2024 earnings: Revenues and EPS in line with analyst expectations Full year 2024 results: US$1.08 loss per share (improved from US$1.22 loss in FY 2023). Revenue: US$28.1m (up 25% from FY 2023). Net loss: US$46.9m (loss narrowed 11% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Annonce • Feb 28
Rapid Micro Biosystems, Inc. Provides Earnings Guidance for the Full Year 2025 Rapid Micro Biosystems, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue of at least $32.0 million, with between 21 and 25 system placements. Annonce • Feb 21
Rapid Micro Biosystems, Inc. to Report Q4, 2024 Results on Feb 28, 2025 Rapid Micro Biosystems, Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 28, 2025 New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$41m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$51.6m market cap). Board Change • Jan 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Chairman of Board Kirk Malloy was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 03
New major risk - Revenue and earnings growth Earnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$47.2m market cap). Annonce • Nov 02
Rapid Micro Biosystems, Inc. Re-Affirms Revenue Guidance for the Full Year 2024 Rapid Micro Biosystems, Inc. re-affirmed revenue guidance for the full year 2024. For the year, the company is reaffirming its full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023, and the placement of at least 20 systems. Reported Earnings • Nov 01
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: US$0.26 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$7.60m (up 24% from 3Q 2023). Net loss: US$11.3m (loss narrowed 15% from 3Q 2023). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 2.0%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Annonce • Oct 24
Rapid Micro Biosystems, Inc. to Report Q3, 2024 Results on Nov 01, 2024 Rapid Micro Biosystems, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 01, 2024 Recent Insider Transactions • Aug 09
Independent Director recently bought US$50k worth of stock On the 6th of August, Richard Kollender bought around 65k shares on-market at roughly US$0.77 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$118k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 04
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.29 loss per share (improved from US$0.33 loss in 2Q 2023). Revenue: US$6.62m (up 32% from 2Q 2023). Net loss: US$12.6m (loss narrowed 10% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 4.8%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Annonce • Jul 18
Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024 Rapid Micro Biosystems, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 02, 2024 Reported Earnings • May 03
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: US$0.31 loss per share (improved from US$0.32 loss in 1Q 2023). Revenue: US$5.61m (up 11% from 1Q 2023). Net loss: US$13.3m (loss narrowed 4.1% from 1Q 2023). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 6.9%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Annonce • Apr 20
Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024 Rapid Micro Biosystems, Inc. announced that they will report Q1, 2024 results Pre-Market on May 03, 2024 Annonce • Apr 10
Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024 Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024, at 09:00 Eastern Standard Time. Agenda: To elect Kirk D. Malloy, Ph.D., Melinda Litherland and Robert Spignesi as Class III Directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified, or until their earlier death, resignation or removal; to consider andatify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions allowing for officer exculpation and To transact such other business. Reported Earnings • Mar 03
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: US$1.22 loss per share (improved from US$1.43 loss in FY 2022). Revenue: US$22.5m (up 31% from FY 2022). Net loss: US$52.5m (loss narrowed 14% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.9%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Annonce • Mar 01
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024 Rapid Micro Biosystems, Inc. provided revenue guidance for the full year 2024. For the full year 2023, the company expects total revenue of at least $27.0 million, including the placement of at least 20 systems. Annonce • Feb 21
Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024 Rapid Micro Biosystems, Inc. announced that they will report fiscal year 2023 results Pre-Market on Mar 01, 2024 Annonce • Feb 03
Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq On February 2, 2024, Rapid Micro Biosystems, Inc. (the Company") received a notification letter from the Nasdaq Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company thatthe bid price for the Company's Class A common stock, par value $0.01 (the common stock") had closed below $1.00 per share for the thirty (30) consecutive business days (December 18, 2023 through February 1, 2024) and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). The notification has no immediate effect on the listing of the Company's common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days to regain compliance with the Bid Price Requirement, which will expire on July 31, 2024 (the Compliance Date"). To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 or higher for a minimum of ten (10) consecutive business days, and in such case, the Staff will provide the Company with written confirmation that it has regained compliance with the Bid Price Requirement. The Staff has the discretion to extend the ten (10) business day period to up to twenty (20) consecutive business days pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar compliance period. To qualify, the Company would need to transfer the listing of the Company's common stock to the Nasdaq Capital Market, provided the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period. If the Company is not eligible or it appears to Nasdaq that the Company will not be able to cure the deficiency during the additional compliance period, Nasdaq will provide written notice to the Company that the Company's common stock will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq's determination to delist its securities. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff, such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and take such reasonable measures to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance for continued listing on Nasdaq. Reported Earnings • Nov 05
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: US$0.31 loss per share (improved from US$0.38 loss in 3Q 2022). Revenue: US$6.15m (up 30% from 3Q 2022). Net loss: US$13.4m (loss narrowed 18% from 3Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 1.1%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Life Sciences industry in the US. Annonce • Nov 04
Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023 Rapid Micro Biosystems, Inc. reaffirmed revenue guidance for the fiscal year 2023. for the year, the company expects its total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022, and the placement of at least 15 systems. Annonce • Oct 20
Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023 Rapid Micro Biosystems, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 03, 2023 Annonce • Sep 20
Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market On September 13, 2023, Rapid Micro Biosystems, Inc. received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that the bid price for the Company’s Class A common stock, par value $0.01 had closed below $1.00 per share for the thirty (30) consecutive business days (July 31, 2023 through September 11, 2023) and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days to regain compliance with the Bid Price Requirement, which will expire on March 11, 2024 (the “Compliance Date”). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten (10) consecutive business days, and in such case, the Staff will provide the Company with written confirmation that it has regained compliance with the Bid Price Requirement. The Staff has the discretion to extend the ten (10) business day period to up to twenty (20) consecutive business days pursuant to Nasdaq Listing Rule 5810(c)(3)(H). Since receiving the notification from the Staff, the closing bid price of the Company’s common stock has been above $1.00 per share from September 12, 2023 through September 19, 2023, a period of six (6) consecutive business days. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar compliance period. To qualify, the Company would need to transfer the listing of the Company’s common stock to the Nasdaq Capital Market, provided the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period. If the Company is not eligible or it appears to Nasdaq that the Company will not be able to cure the deficiency during the additional compliance period, Nasdaq will provide written notice to the Company that the Company’s common stock will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq’s determination to delist its securities. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff, such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and will take all reasonable measures available to the Company to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance for continued listing on Nasdaq. Reported Earnings • Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.33 loss per share (further deteriorated from US$0.31 loss in 2Q 2022). Revenue: US$5.00m (up 30% from 2Q 2022). Net loss: US$14.0m (loss widened 7.1% from 2Q 2022). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Annonce • Jul 23
Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Rapid Micro Biosystems, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 04, 2023 Annonce • Jul 21
Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors Rapid Micro Biosystems, Inc. announced the appointment of Kirk Malloy, Ph.D. as Chair of the Companys Board of Directors . Dr. Malloy will also Chair the Boards Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. Dr. Malloy has more than 25 years of senior management experience in life sciences and in vitro diagnostics with Illumina, Inc., Biosite, Inc. and Qiagen, Inc., and most recently served as Chief Executive Officer of Verogen, Inc., until its acquisition in 2023. Throughout his career, Dr. Malloy has led market development and product development initiatives that have driven revenue growth for early-stage, commercial companies. Dr. Malloy is currently the founder and principal of BioAdvisors, LLC, where he provides strategic consulting services to life sciences, diagnostics and genomics companies. Currently, Dr. Malloy serves on the boards of NanoString Technologies, Inc. and DermTech, Inc. as well as several private genomics tools companies. Dr. Malloy earned a B.S. in Biology &Marine Science from the University of Miami, and an M.S. and Ph.D. in Marine Biology/Biochemistry from the University of Delaware. He has held post-doctoral and instructor positions at Boston University and Northeastern University. The addition of Dr. Malloy brings the total number of directors on the Companys Board to eight. Reported Earnings • May 07
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.32 loss per share (improved from US$0.35 loss in 1Q 2022). Revenue: US$5.04m (up 21% from 1Q 2022). Net loss: US$13.9m (loss narrowed 7.0% from 1Q 2022). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in the US. Major Estimate Revision • Mar 10
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$25.0m to US$22.1m. Forecast losses increased from -US$1.25 to -US$1.33 per share. Life Sciences industry in the US expected to see average net income growth of 3.4% next year. Consensus price target of US$5.88 unchanged from last update. Share price rose 6.0% to US$1.24 over the past week. Reported Earnings • Mar 04
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: US$1.43 loss per share (improved from US$3.94 loss in FY 2021). Revenue: US$17.1m (down 26% from FY 2021). Net loss: US$60.8m (loss narrowed 22% from FY 2021). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 1.1%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Annonce • Feb 17
Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023 Rapid Micro Biosystems, Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Mar 03, 2023 Annonce • Jan 12
Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 Rapid Micro Biosystems, Inc. provided unaudited revenue guidance for the fourth quarter and full year of 2022. For the quarter, the company expects total commercial revenue of between $4.2 million and $4.4 million. For the full year, the company expects total commercial revenue of between $17.0 million to $17.2 million. Annonce • Dec 09
Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology Rapid Micro Biosystems, Inc. announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology. This study, published online by the PDA Journal of Pharmaceutical Science and Technology, sought to evaluate colony counters as an automated compendial microbiological test method and references current regulatory guidelines. In order to simplify validation, all sites followed a modular validation approach that had been developed by the participants. The modular validation facilitates the efficient implementation of the technology to routine use while complying with regulatory requirements. This publication was produced by eight global pharmaceutical companies who implemented and validated an automated colony counting technology to perform quality control microbiology tests, environmental monitoring, bioburden and water testing, in-process product samples and bulk drug substance bioburden. The Growth Direct system has been successfully implemented for routine use in cGMP areas for all applications and QC test requirements mentioned, as well as in-process bioburden testing for new drug applications to the FDA and EMA. Reported Earnings • Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: US$0.38 loss per share (improved from US$0.71 loss in 3Q 2021). Revenue: US$4.74m (down 31% from 3Q 2021). Net loss: US$16.3m (loss narrowed 35% from 3Q 2021). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) missed analyst estimates by 3.5%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Price Target Changed • Nov 12
Price target decreased to US$9.00 Down from US$13.67, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$2.50. The company is forecast to post a net loss per share of US$1.41 next year compared to a net loss per share of US$3.94 last year. Reported Earnings • Nov 12
Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021) Third quarter 2022 results: US$0.38 loss per share (improved from US$0.71 loss in 3Q 2021). Revenue: US$4.74m (down 31% from 3Q 2021). Net loss: US$16.3m (loss narrowed 35% from 3Q 2021). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Annonce • Nov 11
Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook Rapid Micro Biosystems, Inc. reaffirming its prior full year 2022 revenue outlook of at least $17.0 million. Annonce • Nov 03
Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Rapid Micro Biosystems, Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 10, 2022 Annonce • Oct 11
Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System Rapid Micro Biosystems, Inc. announced its newest product, RMBNucleus Mold Alarm, which is designed to rapidly detect environmental molds in the pharmaceutical manufacturing process. RMBNucleus Mold Alarm is expected to be available on the Growth Direct® System before the end of 2022. Slow detection and confirmation of mold contamination continues to be a critical challenge within environmental monitoring at pharmaceutical manufacturing facilities and can compromise products, putting patients at risk. RMBNucleus Mold Alarm, a new software offering for use on the Growth Direct® System, adds rapid detection allowing for early intervention. Annonce • Aug 14
Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID). Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million on June 30, 2022. Kennedy Lewis Investment Management LLC will pay $5 per share in cash. Kennedy Lewis Investment Management LLC has the ability to fully finance this all-cash proposal, and the definitive transaction agreement will not include a financing condition. Transaction is subject to completion of due diligence and execution of definitive documentation acceptable to Kennedy Lewis. Daniel Fisher and Zachary Wittenberg of Akin Gump Strauss Hauer & Feld LLP acted as legal advisor to Kennedy Lewis. Morgan Stanley & Co. LLC acted as financial advisor and Goodwin Procter LLP acted as legal advisor to Rapid Micro Biosystems.
Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) on August 12, 2022. The Board of Directors of Rapid Micro Biosystems, unanimously rejected an unsolicited non-binding proposal from Kennedy Lewis Investment Management LLC as the Board determined that the proposal is inadequate and is not in the best interest of the shareholders. Annonce • Aug 13
Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022 Rapid Micro Biosystems, Inc. revises earnings guidance for the full year 2022. For the year, the company updated its prior revenue outlook to at least $17.0 million. The Company’s lowered guidance reflects expectations for fewer systems placements in fiscal year 2022 as it continues to ramp its commercial team and optimize its commercial execution as well as macro-economic uncertainty that is expected to persist through the second half of the year. Reported Earnings • Aug 12
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: US$0.31 loss per share (up from US$20.01 loss in 2Q 2021). Revenue: US$3.86m (down 37% from 2Q 2021). Net loss: US$13.1m (loss narrowed 5.8% from 2Q 2021). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 78%, compared to a 4.0% growth forecast for the industry in the US. Annonce • Aug 10
Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022 Rapid Micro Biosystems, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022 Annonce • Jul 01
Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million. Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million on June 30, 2022. Kennedy Lewis Investment Management LLC will pay $5.00 per share in cash. Kennedy Lewis Investment Management LLC has the ability to fully finance this all-cash proposal, and the definitive transaction agreement will not include a financing condition. Transaction is subject to completion of due diligence and execution of definitive documentation acceptable to Kennedy Lewis. Daniel I. Fisher of Akin Gump Strauss Hauer & Feld LLP acted as legal advisor to Rapid Micro Biosystems, Inc. Annonce • May 12
Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022 Rapid Micro Biosystems, Inc. announced that it is reaffirming its prior full year 2022 outlook for revenue of between $27 million and $32 million, representing growth of approximately 25% to 50% as compared to the full year 2021. The Company’s full year 2022 revenue outlook assumes that roughly 30% of the revenue will be delivered in the first half of the year, with the remaining 70% in the second half. 
